Sierra Oncology, Inc.
NASDAQ Global MarketCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Nicholas Glover
- Full Time Employees
- 109
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 2150 ? 885 West Georgia Street Vancouver BC Canada 94404
- IPO Date
- Jul 16, 2015
- CIK
- 0001290149
- Website
- sierraoncology.com
- Similar Companies
- Business
- Sierra Oncology, Inc. (SRRA) is a biopharmaceutical company focused on researching, developing, and commercializing targeted therapies for hematology and oncology indications, particularly rare cancers; its lead product is momelotinib (marketed as Ojjaara/Omjjara by GSK), a selective orally bioavailable inhibitor of Janus kinase 1 (JAK1), JAK2, and activin A receptor type 1 (ACVR1) for the treatment of intermediate- or high-risk myelofibrosis patients with anemia, including both newly diagnosed and previously treated individuals; the pipeline previously included SRA515, a selective bromodomain-containing protein 4 (BRD4) inhibitor, and SRA737, an orally bioavailable checkpoint kinase 1 (CHK1) inhibitor, both in early clinical stages targeting solid tumors and hematologic malignancies. Founded in 2003 and headquartered in San Mateo, California, with an additional facility in Vancouver, Canada, the company operates primarily in the United States and Canada, serving patients with unmet needs in myelofibrosis and other oncology settings through clinical-stage assets. In July 2022, GSK plc acquired Sierra Oncology for $1.9 billion in cash at $55 per share, integrating it as a wholly owned subsidiary and advancing momelotinib toward commercialization; GSK secured FDA approval for momelotinib (Ojjaara) in September 2023 for myelofibrosis with anemia regardless of prior therapy, followed by European Commission authorization in January 2024, with US launch occurring in 2024 and ongoing regulatory submissions in markets including Japan.
GSK Receives Regulatory Nod for Consumer Healthcare Demerger
SIERRA ONCOLOGY INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Sierra Oncology, Inc - SRRA
SIERRA ONCOLOGY INVESTOR ALERT - Kuznicki Law PLLC Investigates Proposed Sale of Sierra Oncology, Inc - SRRA
Best Biotech Stocks To Buy Now? 5 To Know
SHAREHOLDER ALERT: Weiss Law Investigates Sierra Oncology, Inc.
Late-Stage Biopharmaceutical Sierra Oncology announces acquisition by GSK
Why Is Sierra Oncology (SRRA) Stock Up Today?
Sierra Oncology Stock Is Soaring: Here's Why
Sierra Oncology Stock Soars After Buyout
GSK to buy Sierra Oncology for $1.9 billion
Sierra Oncology Soars After Takeover by Glaxo
Why Sierra Oncology Stock Is Soaring Today
GlaxoSmithKline Scoops Up Rare Cancer-Focused Sierra Oncology In $1.9B Cash Deal
Why GlaxoSmithKline (GSK) Is Buying Sierra Oncology (SRRA) For $1.9 Billion
GlaxoSmithKline to buy Sierra Oncology for $1.9 billion
GSK to buy Sierra Oncology for $1.9 billion
GSK Reaches Agreement to Acquire Late-Stage Biopharmaceutical Company Sierra Oncology For $1.9bn
Sierra Oncology's Strong Data In Myelofibrosis Challenges MorphoSys And Incyte
Sierra Oncology to Present at B. Riley Securities Oncology Investor Conference
Sierra Oncology: Plenty Of Room To Trade Higher After Latest Myelofibrosis Data